Abstract: The present invention relates to an anthracene derivative compound having a characteristic structure in which an aryl group is introduced into a skeletal structure in which deuterium-substituted phenyl and anthracene are linked. In addition, the present invention relates to a high-efficiency, long-life organic light-emitting device of which the luminous efficiency and lifetime characteristics are significantly improved by employing a polycyclic compound having a characteristic structure as a dopant for a light-emitting layer while employing said compound as a host for the light-emitting layer.

Abstract: The present invention relates to an organic light-emitting diode in which a light-emitting layer comprises a compound represented by [chemical formula A] as a host and comprises a compound represented by [chemical formula 3], [chemical formula 4], [chemical formula 3-1] to [chemical formula 4-3] as a dopant, wherein [chemical formula 3], [chemical formula 4], [chemical formula 3-1] to [chemical formula 4-3] are the same as those described in the detailed description of the invention.

Abstract: A display device includes a substrate including an emission area and a non-emission area; a thin film transistor layer positioned on the substrate; a touch buffer layer positioned on the thin film transistor layer; a connection electrode positioned on the touch buffer layer; a touch insulating layer positioned on the connection electrode; a first electrode positioned on the touch insulating layer, and overlapping the non-emission area; and a first touch sacrificial layer positioned between the touch insulating layer and the first electrode, wherein the first touch sacrificial layer does not overlap the emission area, and is positioned in an island shape while overlapping the non-emission area, and an inclination angle formed between the touch insulating layer and a side surface of the first touch sacrificial layer has an acute angle.

Abstract: Disclosed herein is a die coater capable of effectively simultaneously coating a current collector for a secondary battery with two types of different liquids, which includes a lower block provided with a manifold configured to accommodate a first liquid, an upper block coupled to the lower block and provided with a second liquid inlet, and a coater shim interposed between the upper block and the lower block to form a first slit and a second slit which open toward a front side and are separated from each other, wherein the coater shim is provided with a second liquid flow path on a center guide extending to protrude to the front side across the manifold, and a manifold insert configured to support a bottom surface of the center guide is provided inside the manifold.

Abstract: The present disclosure relates to a novel salt of a 1-sulfonyl pyrrole derivative, and to a novel salt having excellent solubility in vivo, stability, bioavailability, and the like, a preparation method thereof, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin resistance disorder, wherein the pharmaceutical composition includes a GPR40 agonist and an SGLT2 inhibitor, the GPR40 agonist being a compound represented by Formula 1, a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer or the diastereomer, a method of preparing the same, and a method of treating type 2 diabetes mellitus and the like using the same.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: Provided are an improved culture process for reducing unwanted culture byproducts when a target protein is produced in a glutamine-free cell culture medium, an improved culture process for producing a target protein in a glutamine-free cell culture medium, or an improved culture process for producing a target protein in a glutamine-free cell culture medium.

Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.

Abstract: HTS screening was performed regarding cell proliferation, one of symptoms of senescence. As a result, KB1541, which was the most effective on cell proliferation, was earned. The present invention described how the compound regulates cell proliferation and senescence. The present invention uncovered what proteins interacted with the compound using streptavidin-magnetic beads after treating with biotin-connected KB1541. Consequently, it was identified that mitochondrial proteins interacted with the compound. In ATP assay, electron microscope and IP assay, the inventors identified that the compound regulated mitochondrial proteins and thereby increased ATP production as well as recovered senescence.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invent ion relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Abstract: Disclosed are a novel 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and a pharmaceutical use thereof. The 5-membered heterocycle derivatives of Formula I, a tautomer, pharmaceutically acceptable salt, prodrug thereof and compositions containing them are useful for treating a tumor.

Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.